Structure-Based Drug Design in Bioinformatics: Computational Pipelines, Active Site Grid Mapping, and Virtual Screening Workflows

Introduction

Structure-based drug design (SBDD) represents a paradigm in which three-dimensional (3D) structural information of a biological target is used to guide the discovery and optimization of small-molecule inhibitors [1, 2]. In veterinary medicine, SBDD has been applied to a wide range of pathogens, including protozoan parasites, bacterial agents, and viruses that affect livestock, companion animals, and wildlife [3, 4]. The central premise of SBDD is that the atomic-level geometry of a target protein's active site can be exploited to design ligands with high shape and electrostatic complementarity [5, 6]. This approach relies on a series of computational steps that collectively form a pipeline: target selection and structure determination, active site identification and grid mapping, virtual screening of compound libraries, and subsequent validation through molecular dynamics simulations and binding free energy calculations [7, 8].

The integration of bioinformatics tools has accelerated SBDD by enabling large-scale structural comparisons, automated pocket detection, and high-throughput docking simulations [2, 9]. For veterinary applications, SBDD pipelines have been used to target enzymes such as lactate dehydrogenase in Babesia microti [5], thymidylate kinase in Mycoplasma genitalium [10], and UDP-galactopyranose mutase in Brugia malayi [11]. These efforts underscore the importance of computational pipelines in addressing the growing need for novel therapeutics against veterinary pathogens, many of which are developing resistance to existing drugs [12, 13].

This article provides an exhaustive review of the computational components of SBDD, with a focus on pipeline architecture, active site grid mapping methodologies, and virtual screening workflows. Emphasis is placed on the biophysical and algorithmic principles underlying each step, and examples are drawn from veterinary and zoonotic pathogen research.

Computational Pipelines in SBDD

A computational SBDD pipeline is a sequential workflow that transforms raw structural data into a ranked list of candidate inhibitors [7, 14]. The typical pipeline comprises the following stages: (1) target structure acquisition (experimental or homology model), (2) binding site identification and characterization, (3) grid generation for docking, (4) virtual screening of compound libraries, (5) scoring and ranking, and (6) post-docking analysis including molecular dynamics (MD) simulations and binding free energy estimation [1, 4, 15].

The pipeline is often implemented using workflow management systems that allow modular execution and parallelization [7]. For example, a multi-target pipeline for pan-influenza neuraminidase inhibitors employed a consensus scoring approach that integrated physics-based docking with machine learning filters [7]. Similarly, a pipeline targeting the pre-fusion dengue virus envelope protein combined artificial intelligence (AI) based screening with molecular mechanics generalized Born surface area (MM-GBSA) rescoring [4].

A representative SBDD pipeline is illustrated in the following Mermaid diagram:

flowchart TD
    A[Target Selection & Structure Acquisition], > B[Binding Site Identification]
    B, > C[Active Site Grid Mapping]
    C, > D[Compound Library Preparation]
    D, > E[Virtual Screening Docking]
    E, > F[Scoring & Ranking]
    F, > G[Post-Docking Analysis MD/MM-GBSA]
    G, > H[Hit Selection & Experimental Validation]

Each stage involves specific computational tools and algorithms. Target structures may be obtained from X-ray crystallography, cryo-electron microscopy, or homology modeling [16, 17]. For veterinary pathogens where experimental structures are limited, homology models built from related species are frequently used [8, 12]. The quality of the target structure critically influences downstream results; therefore, validation through Ramachandran plots and MolProbity scores is standard practice [18, 19].

Active Site Grid Mapping

Active site grid mapping is the process of discretizing the binding pocket into a 3D grid of points, each assigned energetic properties that guide ligand placement during docking [2, 9]. The grid represents the spatial extent of the binding site and encodes interaction potentials for various atom types (e.g., hydrogen bond donors, acceptors, hydrophobic probes) [3, 6]. Grid resolution typically ranges from 0.2 to 0.5 Å, with finer grids used for detailed electrostatic calculations [5, 20].

The mapping procedure begins with the identification of the binding pocket. Tools such as PocketMaster automate the analysis, clustering, and visualization of protein pocket structural diversity [2]. For enzymes with deep catalytic clefts, such as the M32 metallocarboxypeptidase of Leishmania donovani, grid mapping must account for metal ion coordination and solvent accessibility [1]. In the case of the MexB efflux pump substrate-binding pocket, grid mapping revealed a large, hydrophobic cavity amenable to inhibitor design [9].

Grid maps are typically generated using pre-calculated potential grids that include electrostatic (Coulombic) and van der Waals (Lennard-Jones) terms [15, 20]. Some protocols also include desolvation and hydrogen bonding terms [4]. The grid dimensions are set to encompass the entire binding site plus a margin (often 5-10 Å) to allow ligand flexibility [6]. For targets with multiple binding sites, such as the twin active sites of glyoxalase I, separate grids are generated for each site [15].

The following table summarizes key parameters for active site grid mapping in selected veterinary targets:

Grid mapping is not a static process; iterative refinement based on docking results is common [9]. For example, if top-ranked ligands consistently place a functional group outside the initial grid, the grid may be expanded to include adjacent subpockets [3]. This iterative approach was used in the design of adamantane-based inhibitors of the influenza A M2 proton channel, where grid mapping identified a critical hydrophobic pocket near the channel lumen [6].

Virtual Screening Workflows

Virtual screening (VS) is the computational counterpart of high-throughput screening, where large libraries of compounds are evaluated for binding to a target using docking algorithms [4, 7]. In SBDD, VS workflows are tightly coupled with grid mapping: each compound is docked into the precomputed grid, and its binding pose and affinity are scored [14, 13].

VS workflows can be categorized as structure-based (docking) or ligand-based (pharmacophore, similarity). Structure-based VS is the focus of this article. The workflow typically involves the following steps:

1. Library preparation: Compound databases (e.g., commercial or public libraries) are filtered for drug-like properties using Lipinski's rule of five and other ADMET filters [15, 18]. For veterinary applications, additional filters for metabolic stability in target species may be applied [5].

2. Docking: Each compound is placed into the active site grid using search algorithms (e.g., genetic algorithms, Monte Carlo, or systematic incremental construction) [1, 20]. The scoring function estimates binding free energy as a sum of terms: van der Waals, electrostatic, hydrogen bonding, desolvation, and entropy [3, 10].

3. Consensus scoring: To reduce false positives, multiple scoring functions are combined. For example, a consensus of Glide SP, Glide XP, and MM-GBSA scores was used in a study targeting Plasmodium falciparum MDR1 [13]. Similarly, a physics- and AI-based consensus approach was applied to dengue virus envelope protein [4].

4. Post-docking analysis: Top-ranked compounds undergo MD simulations to assess binding stability and conformational changes [5, 18]. Binding free energies are recalculated using MM-GBSA or MM-PBSA methods [18, 19].

5. Hit selection: Compounds that maintain stable interactions throughout MD and show favorable free energies are selected for experimental testing [14, 15].

A representative VS workflow for veterinary targets is shown in the table below, summarizing recent studies:

The success of VS depends on the quality of the target structure, the accuracy of the scoring function, and the diversity of the compound library [7, 16]. For veterinary pathogens, libraries may be enriched with natural products or known veterinary drugs to facilitate repurposing [11, 21].

Integration of Pipelines, Grid Mapping, and VS: Case Studies

The integration of computational pipelines with grid mapping and VS is exemplified by several recent studies on veterinary and zoonotic pathogens.

Case 1: Babesia microti lactate dehydrogenase. Ali et al. [5] used a structure-based approach to design sanguinarine derivatives targeting B. microti lactate dehydrogenase. The pipeline began with homology modeling of the enzyme, followed by active site grid mapping that identified key residues involved in substrate binding. Virtual screening of a sanguinarine derivative library was performed using Glide SP docking into the precomputed grid. Top hits were subjected to MD simulations and MM-GBSA calculations, leading to the identification of three derivatives with predicted nanomolar affinity [5].

Case 2: Toxoplasma gondii TgAPN2. Altharawi [18] employed a comprehensive SBDD pipeline to identify inhibitors of the M1 aminopeptidase TgAPN2. The binding site was mapped using a grid of 60 x 60 x 60 points with 0.375 Å spacing. Virtual screening of the Asinex library (~250,000 compounds) using Glide SP and XP docking yielded three hits with binding energies below -8.3 kcal/mol. MD simulations confirmed stable binding, and MM-GBSA/PBSA calculations predicted favorable free energies [18].

Case 3: Leptospira species ThiL. Narthanareeswaran et al. [12] targeted the conserved catalytic mechanism of ThiL (thiamine phosphate kinase) in pathogenic Leptospira. The pipeline involved homology modeling, grid mapping of the ATP-binding pocket, and virtual screening of a natural product library. Docking with AutoDock Vina followed by MD simulations identified compounds that formed stable interactions with the catalytic residues [12].

These case studies illustrate how grid mapping and VS are embedded within larger computational pipelines that include target preparation, library filtering, and post-docking validation.

Challenges and Future Directions

Despite its successes, SBDD in veterinary bioinformatics faces several challenges. First, the availability of high-resolution experimental structures for veterinary pathogens remains limited, necessitating reliance on homology models that may lack accuracy in loop regions and side-chain conformations [8, 16]. Second, scoring functions often fail to account for protein flexibility, solvation effects, and entropic contributions, leading to false positives [3, 15]. Third, the translation of computational hits into in vivo efficacy requires consideration of species-specific pharmacokinetics and toxicity [5, 10].

Emerging solutions include the use of ensemble docking to incorporate protein flexibility [7], the application of machine learning to improve scoring functions [4], and the development of specialized veterinary compound libraries [11]. Tools such as PocketMaster [2] and automated pipeline frameworks [7] are making SBDD more accessible to veterinary researchers.

Future directions include the integration of SBDD with immunoinformatics for multi-epitope vaccine design [21, 22] and the use of structural bioinformatics to predict host-pathogen interactions [19, 17]. The growing availability of cryo-EM structures for large veterinary viral complexes will further expand the applicability of SBDD [17].

Conclusion

Structure-based drug design in bioinformatics provides a powerful framework for discovering novel therapeutics against veterinary pathogens. Computational pipelines that integrate active site grid mapping and virtual screening workflows enable the efficient identification of lead compounds. By leveraging structural data from experimental and computational sources, these pipelines have been successfully applied to targets in protozoan, bacterial, and viral pathogens affecting animals. Continued advances in algorithms, computing power, and structural biology will further enhance the impact of SBDD in veterinary medicine.

References

[1] Sen S, Jakkula P, Qureshi IA. Structure-based identification of inhibitory compounds targeting M32 metallocarboxypeptidase of Leishmania donovani. SAR QSAR Environ Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42339821/

[2] Abelyan N. PocketMaster provides a flexible and automated tool for analyzing, clustering, and visualizing structural diversity in protein pockets. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42331856/

[3] Perrone GCM, Spadone S, Francavilla AL, et al. Structural basis of ligand selectivity in FAD/NAD(P)H-dependent dehydrogenases: insights from trypanothione reductase and type II NADH dehydrogenase. Protein Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42322249/

[4] Pravin MA, Khan MA, Singh SK. Identification of potent inhibitors targeting the pre-fusion DENV envelope protein: A consensus physics-and AI-based in silico multi-tier screening approach. Biochem Biophys Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42008872/

[5] Ali MA, Alqahtani T, Sindi ER, et al. Structure-based drug design of sanguinarine derivatives targeting Babesia microti lactate dehydrogenase through computational approaches. J Mol Graph Model. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41932198/

[6] Stampolaki M, Kouridaki ME, Georgiou K, et al. Adamantane-based inhibitors of the influenza A M2 proton channel: structure-based design, biological evaluation, and synthetic approaches. RSC Med Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41908668/

[7] Gevorgyan S, Ayvazyan M, Kharatyan L, et al. Multi-target computational pipeline for discovery of pan-influenza neuraminidase inhibitors. Front Pharmacol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41883499/

[8] Austin K, Obakachi VA, Muzenda FL, et al. Structural characterization of glycolytic enzymes from Trypanosoma cruzi. Mol Biochem Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41713750/

[9] Nanjan P. Structure-Based Drug Design Targeting the Substrate-Binding Pocket of MexB. Protein J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41708976/

[10] Barik K, Kumar M, Arya PK, et al. Targeting thymidylate kinase of Mycoplasma genitalium with phytochemicals: insights from molecular docking and dynamics studies. In Silico Pharmacol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41282963/

[11] Muneeshwari A, Mohan S S. In silico screening of flavonoid-based inhibitors targeting UDP-galactopyranose mutase of Brugia malayi for lymphatic filariasis drug design. Comput Biol Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41205375/

[12] Narthanareeswaran M, Nagarajan H, Subramaniyan S, et al. Probing the conserved catalytic mechanism of ThiL protein in pathogenic Leptospira species: An in silico strategy for inhibitor discovery to combat leptospirosis. Comput Biol Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41662777/

[13] Preetha TL, Yadav V, Subbarao N. In-silico identification of antimalarial compounds targeting PfMDR1 of Plasmodium falciparum. In Silico Pharmacol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41282958/

[14] Madero-Ayala PA, Mares-Alejandre RE, Muñoz-Muñoz PLA, et al. Structure-Based Insights into Stefin-Mediated Targeting of Fowlerpain-1: Towards Novel Therapeutics for Naegleria fowleri Infections. Pharmaceuticals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41304853/

[15] Mohammad Fetian, Q. Al-Balas. Unraveling Potential Glyoxalase-I Inhibitors Utilizing Structure-Based Drug Design Techniques. Advances and Applications in Bioinformatics and Chemistry. 2024. URL: https://www.semanticscholar.org/paper/56277492efb27e074f37e0355c0b54dc59602319

[16] Franklin M, Cheung J, Rudolph M, et al. Structural genomics for drug design against the pathogen Coxiella burnetii. Proteins: Structure, Function, and Bioinformatics. 2015. URL: https://www.semanticscholar.org/paper/24fc16e7624aef8da3c9349589a046dda494e638

[17] Waman VP, Sen N, Varadi M, et al. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Briefings Bioinform. 2020. URL: https://www.semanticscholar.org/paper/77eba94adf1779e1a46e79f43cb6e5dd19598be1 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[18] Altharawi A. Targeting Toxoplasma gondii ME49 TgAPN2: A Bioinformatics Approach for Antiparasitic Drug Discovery. Molecules. 2023. URL: https://www.semanticscholar.org/paper/888ff1cca23908f4e0a04eb368a67cf6155b589d

[19] Vetrivel U, Nagarajan H, Thirumudi I. Design of inhibitory peptide targeting Toxoplasma gondii RON4-human beta-tubulin interactions by implementing structural bioinformatics methods. Journal of Cellular Biochemistry. 2018. URL: https://www.semanticscholar.org/paper/eb511d5cd5fa8a5dbeba7fcee61f220be66cc690

[20] Gschwend DA, Sirawaraporn W, Santi D, et al. Specificity in structure-based drug design: Identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Proteins: Structure, Function, and Bioinformatics. 1997. URL: https://www.semanticscholar.org/paper/4e9febf0473980f2fd3d12b77d9f9051c118c322

[21] Saha S, Vashishtha S, Kundu B, et al. In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani. BMC Bioinformatics. 2022. URL: https://www.semanticscholar.org/paper/79af7efdbc1c3f961e39537b39417f24c3232365

[22] Mahalik P, Tanya M, Pradhan S, et al. Immunoinformatics Approach for the Prediction of Novel Peptide-based Epitope Vaccine Design Against Leishmania Donovani: a Computational Biology Approach. International Journal For Multidisciplinary Research. 2023. URL: https://www.semanticscholar.org/paper/ac01e7004eca3d1bc7a9a876c470b18011ecc23c